

Freedom of Information Act 2000 - Request Reference FoI/23/181
Haemophilia A across the UK

Information Requested:

- 1. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease.**

Mild: 44

Moderate: 12

Severe: 19

Total: 75

- 2. In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products?**

- Advate - 3
- Adynovi – 0
- Elocta – 0
- Esperoct – 0
- Factor Eight Inhibitor Bypass Activity (FEIBA) – 0
- Hemlibra (standalone) - 0
- Hemlibra in combination with any Factor VIII – 1
- NovoEight – 0
- NovoSeven RT – 0
- Obizur – 0
- Refacto AF – 0
- Any other products:
 - Voncento – 1
 - Veyvondi – 1

- 3. For patients treated with Advate in the last three months, please provide:**

- **the number of haemophilia A patients treated prophylactically**

0

- **the number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds)**

3

- 4. In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY?**

- Advate – 1
- Adynovi – 0
- Elocta – 0

- Esperoct – 0
- Factor Eight Inhibitor Bypass Activity (FEIBA) – 0
- Hemlibra (standalone) – 0
- Hemlibra in combination with any Factor VIII – 1
- NovoEight – 0
- NovoSeven RT – 0
- Obizur – 0
- Refacto AF – 0
- Any other products:
 - Voncento – 1
 - Veyvondi – 1